Regulatory T-cells and Crohn's Disease (CrohnReg)
The Effect of Infliximab Therapy in Crohn Patients on Regulatory T-cells
Aim: the main aim of this study is to investigate if immune cells (regulatory T-cells, Th17 cells and other immune cell types) or biomarkers can be used to predict the response or lack of response to treatment with Infliximab. If so, characteristics of the immune cells may also unveil the mechanisms behind lack of response to Infliximab.
Design: a prospective, observational study with three arms. In the treatment group, 35 patients with Crohn's disease about to start Infliximab-treatment are recruited. They have blood samples drawn at day 1 before first treatment, after 6 week, and again after 22 weeks of treatment. 12 healthy volunteers serve as a control group. Controls are only investigated once. All treatment and follow-up are according to national guidelines, and data from this study is not used by the clinicians.
Methods: the number of regulatory T-cells and pro-inflammatory T-cells (Th17 cells) is investigated using flow cytometry. From plasma and serum samples, various proteins (biomarkers), such as transforming growth factor beta (TGF-beta) and tumour necrosis factor alpha (TNF-alpha), are measured using immunoassays. Patient data (demographics and medical history) are extracted from various registries.
Обзор исследования
Подробное описание
Primary analyses: patient response to Infliximab treatment is quantified using Harvey Bradshaw Index, and the response is then related to the number of regulatory T-cells, Th17 cells, and biomarker levels at baseline. The exact cut-off for response vs. non-respons will be determined and validated once all data is collected by an assessor blinded for the flow cytometry results and biomarker levels.
Plan for missing data: for patients with missing Harvey Bradshaw Index, we will first try to re-create the score using the patient records (information on well-being, abdominal pain, diarrhea, fistulae/abscesses, and extra-intestinal Crohn manifestations). If this is not possible, an experienced clinician will rate the patient's Infliximab response based on all available patient record data, but blinded for flow cytometry results and biomarker levels.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Copenhagen
-
Hvidovre, Copenhagen, Дания, 2650
- Hvidovre Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Patients from the gastroenterology department at Hvidovre Hospital and Køge Sygehus are eligible for entry.
Healthy controls are recruited by advitising at Hvidovre Hospital.
Описание
Infliximab group
Inclusion Criteria:
- Crohn's Disease
- Starting Infliximab treatment
- Patient at the gastrointestinal department at Hvidovre Hospital or Køge Sygehus
- Can understand and write Danish
- European ancestry
Exclusion Criteria:
- Not able to consent in an ethical manner (e.g. severe mental illness)
- Significant co-morbidity (e.g. cancer, HIV)
- Other immunological disease (e.g. psoriasis)
- Current treatment with biological agents
Healthy controls
Inclusion Criteria:
- No current disease
- No daily drug use
- Can understand and write Danish
- European ancestry
Exclusion Criteria:
- Not able to consent in an ethical manner (e.g. severe mental illness)
- Significant co-morbidity (e.g. cancer, HIV)
- Other immunological disease (e.g. psoriasis)
- Current treatment with biological agents
Учебный план
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Infliximab
35 Crohn patients about to start Infliximab treatment, gives as i.v.
injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
|
The patients are included in the study when the decision to treat with Infliximab is already made.
This study is observational, and all treatment and clinical follow-up are according to national guidelines.
|
|
Healthy controls
12 healthy controls without Crohn's Disease.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from baseline in number of regulatory T-cells at 6 weeks
Временное ограничение: Baseline, 6 weeks (plus/minus 1 week)
|
The number of regulatory T-cells is measured in fresh blood by flow cytometry.
|
Baseline, 6 weeks (plus/minus 1 week)
|
|
Change from baseline in number of regulatory T-cells at 22 weeks
Временное ограничение: Baseline, 22 weeks (plus/minus 1 week)
|
The number of regulatory T-cells is measured in fresh blood by flow cytometry.
|
Baseline, 22 weeks (plus/minus 1 week)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from baseline in Harvey Bradshaw Index at 6 weeks
Временное ограничение: Baseline, 6 weeks (plus/minus 1 week)
|
Harvey Bradshaw Index is a measure of Crohn's Disease severity.
|
Baseline, 6 weeks (plus/minus 1 week)
|
|
Change from baseline in CD161 expression at 6 weeks
Временное ограничение: Baseline, 6 weeks (plus/minus 1 week)
|
Cluster of differentiation 161 (CD161) is a T helper 17 cell (Th17)-marker, measured by flow cytometry of fresh blood samples.
|
Baseline, 6 weeks (plus/minus 1 week)
|
|
Change from baseline in CD161 expression at 22 weeks
Временное ограничение: Baseline, 22 weeks (plus/minus 1 week)
|
CD161 is a Th17-marker, measured by flow cytometry of fresh blood samples.
|
Baseline, 22 weeks (plus/minus 1 week)
|
|
Change from baseline in cytokine levels at 6 weeks
Временное ограничение: Baseline, 6 weeks (plus/minus 1 week)
|
We will measure IFN-gamma, IL-4, IL-6, IL-7, IL-10, IL-15, IL-17, and TNF-alpha by Luminex.
TGF-beta, suPAR, and IL-15 will be measured by ELISA.
|
Baseline, 6 weeks (plus/minus 1 week)
|
|
Change from baseline in cytokine levels at 22 weeks
Временное ограничение: Baseline, 22 weeks (plus/minus 1 week)
|
We will measure IFN-gamma, IL-4, IL-6, IL-7, IL-10, IL-15, IL-17, and TNF-alpha by Luminex.
TGF-beta, suPAR, and IL-15 will be measured by ELISA.
|
Baseline, 22 weeks (plus/minus 1 week)
|
|
Change from baseline in Harvey Bradshaw Index at 22 weeks
Временное ограничение: Baseline, 22 weeks (plus/minus 1 week)
|
Harvey Bradshaw Index is a measure of Crohn's Disease severity.
|
Baseline, 22 weeks (plus/minus 1 week)
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Ove Andersen, MD, PhD, Hvidovre Hospital & University of Copenhagen
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- H-1-2013-072
- HVH-2013-028 (Идентификатор реестра: Datatilsynet)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .